RESUSCITEC
Desconocido
CIRDinnova: Shifting the limits of resuscitation with CIRD Controlled Integrated Resuscitation Device
RESUSCITEC GMBH
participó en un
H2020:
H2020-FTIPilot-2016
Sudden cardiac arrest is one of the most frequent causes of death. But only 3% of the patients survive out-of-hospital resuscitation, and on...
2016-09-13 - 2022-05-31 | Financiado
2016-09-13 - 2022-05-31 | Financiado
CIRDvalid: CIRDvalid Clinical validation of a set of 11 biomarkers and a system of diagnostic and therapeutic...
RESUSCITEC GMBH
tramitó un
H2020:
H2020-SMEInst-2014-2015
For decades there has been no significant improvement in resuscitation-therapy of patients suffering from cardiac arrest. Only 3% survive ou...
2015-05-25 - 2015-09-30 | Financiado
2015-05-25 - 2015-09-30 | Financiado
* No se disponen de datos de la empresa actual.